Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Malignant Melanoma

  Free Subscription


10.06.2019

1 Br J Dermatol
1 Cancer Res
6 J Am Acad Dermatol
1 J Cell Physiol
3 Lancet Oncol
1 Melanoma Res
1 N Engl J Med
4 Nat Med
1 PLoS Comput Biol
3 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Br J Dermatol

  1. MCINERNEY-LEO AM, Finnane A
    The personal touch: does the communication method affect response to melanoma genetic risk?
    Br J Dermatol. 2019;180:1288-1289.
    PubMed     Text format    


    Cancer Res

  2. SAHU RP
    Deciphering Mechanisms of UVR-Induced Tumoral Immune Checkpoint Regulation against Melanoma.
    Cancer Res. 2019;79:2805-2807.
    PubMed     Text format     Abstract available


    J Am Acad Dermatol

  3. ZHANG S, Liu R, Siripong N, Kirkwood J, et al
    Thick Melanoma Is Associated with Low Melanoma Knowledge and Low Perceived Health Competence, but Not Delays in Care.
    J Am Acad Dermatol. 2019 May 28. pii: S0190-9622(19)30872.
    PubMed     Text format    

  4. BRODELL RT
    JAAD Game Changers: Variability in mitotic figures in serial sections of thin melanomas.
    J Am Acad Dermatol. 2019 May 28. pii: S0190-9622(19)30856.
    PubMed     Text format    

  5. CHOI FD, Kraus CN, Elsensohn AN, Carley SK, et al
    PD-1 and PD-L1 inhibitors in the treatment of non-melanoma skin cancer: a systematic review.
    J Am Acad Dermatol. 2019 Jun 1. pii: S0190-9622(19)30881.
    PubMed     Text format     Abstract available

  6. RIQUELME-MC LOUGHLIN C, Podlipnik S, Bosch-Amate X, Riera-Monroig J, et al
    Diagnostic accuracy of imaging studies for initial staging of T2b-T4b melanoma patients. A cross-sectional study.
    J Am Acad Dermatol. 2019 Jun 1. pii: S0190-9622(19)30880.
    PubMed     Text format     Abstract available

  7. BARANOWSKI MLH, Yeung H, Chen SC, Gillespie TW, et al
    Factors Associated with Time to Surgery in Melanoma: An Analysis of the National Cancer Database.
    J Am Acad Dermatol. 2019 Jun 1. pii: S0190-9622(19)30883.
    PubMed     Text format     Abstract available

  8. ELLISON PM, Zitelli JA, Brodland DG
    Mohs Surgery for Melanoma; A Prospective Multicenter Study.
    J Am Acad Dermatol. 2019 May 28. pii: S0190-9622(19)30861.
    PubMed     Text format     Abstract available


    J Cell Physiol

  9. XIA Y, Zhou Y, Han H, Li P, et al
    lncRNA NEAT1 facilitates melanoma cell proliferation, migration, and invasion via regulating miR-495-3p and E2F3.
    J Cell Physiol. 2019 Jun 7. doi: 10.1002/jcp.28559.
    PubMed     Text format     Abstract available


    Lancet Oncol

  10. HELMINK B, Wargo JA
    Neoadjuvant therapy for melanoma: is it ready for prime time?
    Lancet Oncol. 2019 Jun 3. pii: S1470-2045(19)30377.
    PubMed     Text format    

  11. ROZEMAN EA, Menzies AM, van Akkooi ACJ, Adhikari C, et al
    Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.
    Lancet Oncol. 2019 May 31. pii: S1470-2045(19)30151.
    PubMed     Text format     Abstract available

  12. LONG GV, Saw RPM, Lo S, Nieweg OE, et al
    Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF(V600) mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial.
    Lancet Oncol. 2019 Jun 3. pii: S1470-2045(19)30331.
    PubMed     Text format     Abstract available


    Melanoma Res

  13. DIAMANTOPOULOS PT, Lakiotaki E, Kyriakakis G, Gogas H, et al
    New primary melanoma in a patient under triple therapy with vemurafenib, cobimetinib, and atezolizumab for metastatic melanoma.
    Melanoma Res. 2019 May 30. doi: 10.1097/CMR.0000000000000627.
    PubMed     Text format     Abstract available


    N Engl J Med

  14. ROBERT C, Grob JJ, Stroyakovskiy D, Karaszewska B, et al
    Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
    N Engl J Med. 2019 Jun 4. doi: 10.1056/NEJMoa1904059.
    PubMed     Text format     Abstract available


    Nat Med

  15. SULLIVAN RJ, Hamid O, Gonzalez R, Infante JR, et al
    Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients.
    Nat Med. 2019 Jun 6. pii: 10.1038/s41591-019-0474.
    PubMed     Text format     Abstract available

  16. ROZEMAN EA, Blank CU
    Combining checkpoint inhibition and targeted therapy in melanoma.
    Nat Med. 2019 Jun 6. pii: 10.1038/s41591-019-0482.
    PubMed     Text format    

  17. ASCIERTO PA, Ferrucci PF, Fisher R, Del Vecchio M, et al
    Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.
    Nat Med. 2019 Jun 6. pii: 10.1038/s41591-019-0448.
    PubMed     Text format     Abstract available

  18. RIBAS A, Lawrence D, Atkinson V, Agarwal S, et al
    Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
    Nat Med. 2019 Jun 6. pii: 10.1038/s41591-019-0476.
    PubMed     Text format     Abstract available


    PLoS Comput Biol

  19. SU Y, Bintz M, Yang Y, Robert L, et al
    Phenotypic heterogeneity and evolution of melanoma cells associated with targeted therapy resistance.
    PLoS Comput Biol. 2019;15:e1007034.
    PubMed     Text format     Abstract available


    PLoS One

  20. YAN Y, Leontovich AA, Gerdes MJ, Desai K, et al
    Understanding heterogeneous tumor microenvironment in metastatic melanoma.
    PLoS One. 2019;14:e0216485.
    PubMed     Text format     Abstract available

  21. VON HACHT JL, Erdmann S, Niederstadt L, Prasad S, et al
    Increasing molar activity by HPLC purification improves 68Ga-DOTA-NAPamide tumor accumulation in a B16/F1 melanoma xenograft model.
    PLoS One. 2019;14:e0217883.
    PubMed     Text format     Abstract available

  22. KOS S, Lopes A, Preat V, Cemazar M, et al
    Intradermal DNA vaccination combined with dual CTLA-4 and PD-1 blockade provides robust tumor immunity in murine melanoma.
    PLoS One. 2019;14:e0217762.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: